Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Stevenson, M. orcid.org/0000-0002-3099-9877, Pandor, A. orcid.org/0000-0003-2552-5260, Hamilton, J. et al. (5 more authors) (2018) Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. ISSN 1170-7690

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © Springer International Publishing AG, part of Springer Nature 2018. This is an author produced version of a paper subsequently published in PharmacoEconomics. Uploaded in accordance with the publisher's self-archiving policy.
Dates:
  • Published: 3 March 2018
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Sheffield Centre for Health and Related Research
Funding Information:
FunderGrant number
NATIONAL INSTITUTE FOR HEALTH RESEARCH14/25/02
Depositing User: Symplectic Sheffield
Date Deposited: 07 Mar 2018 11:30
Last Modified: 03 Mar 2019 01:38
Published Version: https://doi.org/10.1007/s40273-018-0624-7
Status: Published online
Publisher: Springer Verlag
Refereed: Yes
Identification Number: https://doi.org/10.1007/s40273-018-0624-7
Related URLs:

Share / Export

Statistics